Bris­tol My­ers got the first TYK2 ap­proval. Fra­zier’s new biotech Su­do hopes to get many more

Ear­li­er in Sep­tem­ber, the FDA ap­proved a TYK2 in­hibitor for the first time, a drug from Bris­tol My­ers Squibb for pso­ri­a­sis, with­out slap­ping on the black box safe­ty warn­ing that has cast a shad­ow on the larg­er fam­i­ly of an­ti-in­flam­ma­to­ry drugs it comes from, the JAK in­hibitors.

While Bris­tol My­ers won the first ap­proval, it’s fol­lowed by a suite of oth­ers with TYK2 pro­grams. Now, Fra­zier’s join­ing the fray.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER